Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Cash & Equivalents (2021 - 2025)

PAVmed (PAVM) has 5 years of Cash & Equivalents data on record, last reported at $4.0 million in Q2 2025.

  • For Q2 2025, Cash & Equivalents fell 84.3% year-over-year to $4.0 million; the TTM value through Jun 2025 reached $4.0 million, down 84.3%, while the annual FY2024 figure was $1.2 million, 93.97% down from the prior year.
  • Cash & Equivalents reached $4.0 million in Q2 2025 per PAVM's latest filing, up from $2.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $77.3 million in Q4 2021 and bottomed at $1.2 million in Q4 2024.
  • Average Cash & Equivalents over 5 years is $35.6 million, with a median of $37.3 million recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 52.07% in 2022, then crashed 93.97% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $77.3 million in 2021, then plummeted by 48.56% to $39.7 million in 2022, then plummeted by 50.59% to $19.6 million in 2023, then plummeted by 93.97% to $1.2 million in 2024, then surged by 237.89% to $4.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $4.0 million in Q2 2025, $2.7 million in Q1 2025, and $1.2 million in Q4 2024.